Jean-Jacques Bienaime with Jennifer Kano
Jean-Jacques Bienaimé BioMarin | The CEO Magazine
BioMarin's CEO Bienaime, in his 16th year at the helm, scores $18M pay package | FiercePharma
BioMarin Pharmaceutical loss shrinks 34% in 2018, 92% in 4Q
Search Images - Patrick McMullan
Jean Jacques Bienaime Sells 1,500 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock - Opera News
Kim Dolan - Brand Manager, North America PKU - BioMarin Pharmaceutical Inc. | LinkedIn
Jennifer Beinaime with Jean-Jacques Bienaime
BioMarin's CEO On Its Product Pipeline
Jean-Jacques Bienaime - Crunchbase Person Profile
Jean-Jacques Bienaime with Jennifer Kano
Rare Diseases | LOTUS EDITIONS
J.P. Morgan Healthcare Conference is under way: early themes and a podcast - San Francisco Business Times
People | Nature Biotechnology
BioMarin was ranked fourth on the 2019 list of "America's Best Midsize Employers" by Forbe's magazine
On the Line: BioMarin Pharma's CEO Jean Jacques Bienaime
Michel Vounatsos vs Jean Jacques Bienaime | Comparably
BioMarin Pharmaceutical (NASDAQ: BMRN) wins FDA approval for $700,000 Batten disease drug Brineura - San Francisco Business Times
Jean Reno - Wikipedia
BioMarin Pharmaceutical shares rise after possible takeover from Roche
Jan-Jacques Bienaime with Lana Bondar
Jennifer Bienaime with Jean-Jacques Bienaime
Biotech SF: BioMarin shares rise on data from late-stage rare disease trial
Jean Jacques Bienaime - Board Member - PhRMA Foundation | LinkedIn
BioMarin betting big on smaller patient groups - San Francisco Business Times
jean-jacques-bienaime-biomarin-ceo | North Bay Life Science Alliance
BioMarin (NASDAQ: BMRN) sues to stop Dr. Reddy's (NYSE: RDY) from selling generic version of PKU drug Kuvan - San Francisco Business Times
